AARD
NASDAQAardvark Therapeutics Inc.
Aardvark Therapeutics Inc. (AARD) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 8 wire items for AARD, including 3 insider trades, 2 earnings updates and 2 SEC filings. The most recent was published Nov 10, 2026.
AARD rankings
Financial highlights
Full financials- Revenue, TTM
- $2.05M
- Revenue growth
- -36.2%
- Net income, TTM
- -$69.89M
- Net margin
- -3415.9%
- Cash
- $73.85M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks26+33%
2026-05-172026-11-08
Mix2090d
- Insider10(50%)
- SEC Filings4(20%)
- Earnings2(10%)
- Other2(10%)
- Offering1(5%)
- Market1(5%)
Activity · 52 weeks6332 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- INSIDERChief Executive Officer Lee Tien-Li was granted 793,951 stock options and returned 793,951 stock options to the company (SEC Form 4)4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
- INSIDEROfficer Sun Nelson was granted 304,094 stock options and returned 304,094 stock options to the company (SEC Form 4)4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
- INSIDERChief Medical Officer Jaiman Manasi was granted 374,560 stock options and returned 374,560 stock options to the company (SEC Form 4)4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
- ANALYSTAardvark Therapeutics downgraded by Raymond JamesRaymond James downgraded Aardvark Therapeutics from Strong Buy to Mkt Perform
- SECSEC Form 8-K filed by Aardvark Therapeutics Inc.8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- PRAardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension TrialsHERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratoryHQ-CT scores fell by Week 2 of dose escalation on ARD-101 and returned to near baseline within two weeks of stopping treatment, with less rebound on placeboOLE participants switching from placebo to ARD-101 saw a further reduction in HQ-CT scores by Day 28ARD-101 was well tolerated; most adverse events mild to moderateFDA lifted full clinical hold on ARD-101; Company plans to request FDA meeting to align on new Phase 3 trial design and expects to resume PWS clinical activities in 2027Conference call and webcast today at 8:00 a.m. ET SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE)
- SECSEC Form 8-K filed by Aardvark Therapeutics Inc.8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- PRAardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE DataClinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume Aardvark will host a webcast to review available dataset from the terminated Phase 3 HERO trial and OLE trial on Friday, October 23, 2026, at 8:00 a.m. EST SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (NASDAQ:AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome (PWS) and metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company’s Investigational New Drug applicatio
- NEWSAARD UPCOMING DEADLINE: Levi & Korsinsky Alerts Aardvark Therapeutics, Inc. Stockholders of Securities Class Action - Contact the FirmAARD INVESTOR ALERT NEW YORK CITY, NY / ACCESS Newswire / October 9, 2026 / "Investors deserve transparency about material risks that could affect their investments, and the allegations here center on whether Aardvark's representations about ARD-101's prospects reflected what was actually known about the candidate's safety profile,"* said Joseph E. Levi, Esq. Levi & Korsinsky, LLP alerts investors in Aardvark Therapeutics, Inc. (NASDAQ:AARD) of a pending securities class action covering purchasers between February 13, 2025 and May 14, 2026. Check if you might be eligible to recover your investment losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or ☎(212) 363-7500.Shar
- INSIDERSEC Form 4 filed by Aardvark Therapeutics Inc.4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
- INSIDERSEC Form 3 filed by Aardvark Therapeutics Inc.3 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
- SECSEC Form 8-K filed by Aardvark Therapeutics Inc.8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- PRAardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of DirectorsBrings more than 25 years of experience in clinical strategy, biostatistics and regulatory submissions from Abivax, Alumis, MyoKardia and Genentech/Roche SAN DIEGO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the appointment of David Zhang, Ph.D., MBA, to its Board of Directors, effective October 7, 2026. Dr. Zhang will serve as an independent director. "David has spent more than 25 years designing clinical programs, analyzing pivotal t
- PRAardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that on October 1, 2026, one new employee was granted an inducement award consisting of a stock option to purchase 60,000 shares of common stock. The option was granted pursuant to the Aardvark Therapeutics, Inc. 2025 Inducement Equity Incentive Plan and was granted as an inducement material to the employee’s employment with Aardvark in accordance with Nasdaq Listing Rule 5635(c)(4). The exerci
- INSIDEROfficer Sun Nelson sold $394,957 worth of shares (76,754 units at $5.15) as part of a pre-agreed trading plan, decreasing direct ownership by 68% to 35,475 units (SEC Form 4)4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
- INSIDERSEC Form 4 filed by Director Chi Jeffrey4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
- INSIDERSEC Form 4 filed by Director Graf Susan E4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
- INSIDERSEC Form 4 filed by Director Baynes Roy D.4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
- INSIDERSEC Form 4 filed by Director Tong Victor Edward Jr4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
- SECAardvark Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- SECSEC Form 10-Q filed by Aardvark Therapeutics Inc.10-Q - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- SECAardvark Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- PRAardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdatesAssessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in the third quarter of 2026 to support an informed determination of next steps Remains in active discussions with the FDA to support resolution of the clinical hold for ARD-101 program $73.9 million in cash, cash equivalents and short-term investments as of June 30, 2026, supports projected operations into late 2027 SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported
- SECSEC Form DEF 14A filed by Aardvark Therapeutics Inc.DEF 14A - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- SECSEC Form PRE 14A filed by Aardvark Therapeutics Inc.PRE 14A - Aardvark Therapeutics, Inc. (0001774857) (Filer)
AARD FAQ
10 questionsWhat is the latest news on AARD?
In the last 30 days Quantisnow tracked 8 wire items for AARD: 3 insider trades, 2 earnings updates, 2 SEC filings and 1 analyst rating. The most recent was published on November 10, 2026.What is AARD revenue?
Aardvark Therapeutics Inc. (AARD) reported $2.05M of revenue for the twelve months ended Jun 30, 2026. That is down 36.2% from the year before. Revenue for fiscal 2025 was $0.Is AARD profitable?
No. Aardvark Therapeutics Inc. reported a net loss of $69.89M for the twelve months ended Jun 30, 2026.How much cash and debt does AARD have?
Aardvark Therapeutics Inc. reported $73.85M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does AARD stock trade?
Aardvark Therapeutics Inc. (AARD) is listed on NASDAQ.What sector and industry is AARD in?
Aardvark Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Aardvark Therapeutics Inc. go public?
Aardvark Therapeutics Inc. (AARD) completed its IPO in 2025.What are analysts saying about AARD?
Across the last 8 analyst actions on Aardvark Therapeutics Inc., there were 0 upgrades and 6 downgrades. The most recent action was from Raymond James: Mkt Perform on 2026-11-05.What companies are similar to AARD?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare AARD side-by-side with any of them on Quantisnow.How can I track AARD on Quantisnow?
Quantisnow aggregates Aardvark Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AARD to receive live email and push alerts on every new disclosure.